US2014066455A1PendingUtilityA1

Novel compounds

Assignee: ASTRAZENECA ABPriority: Dec 21, 2006Filed: Nov 13, 2013Published: Mar 6, 2014
Est. expiryDec 21, 2026(~0.4 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 43/00A61P 35/02C07D 409/14C07D 401/12C07D 413/12C07D 405/12C07D 231/40C07D 471/04C07D 409/12C07D 403/12C07D 487/04A61K 31/415C07D 405/06C07D 401/14C07D 401/06
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

Claims

exact text as granted — not AI-modified
1 . A method of treating cancer which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         2 . The method of  claim 1 , wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, prostrate cancer and multiple myeloma. 
     
     
         3 . A pharmaceutical composition comprising a compound of formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

Join the waitlist — get patent alerts

Track US2014066455A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.